Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but...

ver descrição completa

Detalhes bibliográficos
Autores: Ortiz-Maldonado Gibson, Valentín, Rives Solà, Susana, Español Rego, Marta, Alonso Saladrigues, A., Montoro, Mercedes, Magnano, Laura, Giné Soca, Eva, Pascal i Capdevila, Mariona, Díaz Beyà, Marina, Castellà Castellà, Maria, Català, Albert, Faura, Anna, Rodríguez Lobato, Luis Gerardo, Oliver Caldés, Aina, Martínez-Roca, Alexandra, Rovira, Montserrat, González Navarro, E. Azucena, Ortega, Juan Ramón, Cid Vidal, Joan, Lozano, Miquel, García Rey, Enric, Fernández, Sara (Fernández García), Castro Rebollo, Pedro, Jordán García, Iolanda, Villamor i Casas, Neus, Aymerich Gregorio, Marta, Torrebadell Burriel, Montserrat, Deyá, Angela, Fernández de Larrea Rodríguez, Carlos José, Benítez-Ribas, Daniel, Trias, Esteve, Varea, Sara, Calvo Rojas, Gonzalo, Esteve Reyner, Jordi, Urbano Ispizua, Álvaro, Juan, Manel, Delgado, Julio (Delgado González)
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/193208
Acesso em linha:https://hdl.handle.net/2445/193208
Access Level:Acceso aberto
Palavra-chave:Leucèmia limfocítica crònica
Cèl·lules canceroses
Teràpia cel·lular
Antígens CD
Immunoteràpia
Receptors cel·lulars
Chronic lymphocytic leukemia
Cancer cells
Cellular therapy
CD antigens
Immunotheraphy
Cell receptors
Descrição
Resumo:The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age.

Registros relacionados